Continuing our coverage on vaccines. Results of the third phase clinical trials for Coronavac by China's Sinovac stirred confusion over the past weeks.<br /><br />A study for the vaccine conducted in Brazil obtained a 50.4 percent efficacy, slightly over the minimum 50 percent set by the WHO.<br /><br />While clinical trials in Turkey obtained a 91.2 percent efficacy rate.
